Clinical Trials
15
Active:2
Completed:4
Trial Phases
0 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Methylation Biomarkers for Pioneering Early Esophageal Cancer Detection
Completed
- Conditions
- Esophageal Cancer
- First Posted Date
- 2025-03-26
- Last Posted Date
- 2025-04-01
- Lead Sponsor
- Singlera Genomics Inc.
- Target Recruit Count
- 1069
- Registration Number
- NCT06895551
- Locations
- 🇨🇳
Cancer hospital, Chinese academy of medical sciences, Beijing, Beijing, China
Hepatocellular Carcinoma 3 Gene Methylation Combination Detection Kit (PCR Fluorescent Probe Method) Multicenter Clinical Trial
Active, not recruiting
- Conditions
- Hepatocellular Carcinoma (HCC)
- First Posted Date
- 2025-02-24
- Last Posted Date
- 2025-07-09
- Lead Sponsor
- Singlera Genomics Inc.
- Target Recruit Count
- 900
- Registration Number
- NCT06842563
- Locations
- 🇨🇳
Zhongshan Hospital Affiliated to Fudan University in Shanghai, Shanghai, Shanghai, China
INSPIRE: a Multi-Cancer Early Detection Study
Recruiting
- Conditions
- Liver CancerGastric CancerPancreatic CancerBreast CancerOvarian CancerColorectal CancerEsophageal CancerCervical CancerEndometrial CancerBladder Cancer
- First Posted Date
- 2024-06-03
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- Singlera Genomics Inc.
- Target Recruit Count
- 5350
- Registration Number
- NCT06440018
- Locations
- 🇨🇳
Fudan University, Shanghai, Shnaghai, China
Clinical Validation of ColonAiQ (a Blood-based Assay Targeting ctDNA Methylation) for Colorectal Cancer Detection
Completed
- Conditions
- Colorectal Cancer
- First Posted Date
- 2024-04-04
- Last Posted Date
- 2024-06-03
- Lead Sponsor
- Singlera Genomics Inc.
- Target Recruit Count
- 1965
- Registration Number
- NCT06347887
- Locations
- 🇨🇳
The Affiliated Hospital of Xuzhou Medical University, Xuzhou, Jiangsu, China
🇨🇳Cancer Hospital Affiliated to Shandong First Medical University (Shandong Institute of Cancer Prevention and Control, Shangdong Cancer Hospital), Jinan, Shandong, China
🇨🇳Shanxi Provincial People's Hospital, Taiyuan, Shanxi, China
Clinical Research on Dynamic Monitoring MRD Via Plasma ctDNA After Systemic Therapy of Hepatocellular Carcinoma
Recruiting
- Conditions
- Hepatocellular Carcinoma
- First Posted Date
- 2023-12-21
- Last Posted Date
- 2024-01-03
- Lead Sponsor
- Singlera Genomics Inc.
- Target Recruit Count
- 475
- Registration Number
- NCT06178809
- Locations
- 🇨🇳
Fudan university Zhongshan Hospital, Shanghai, Shanghai, China
- Prev
- 1
- 2
- 3
- Next
News
No news found